Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the target of a large decrease in short interest in December. As of December 15th, there was short interest totaling 489,427 shares, a decrease of 18.6% from the November 30th total of 601,240 shares. Based on an average daily volume of 120,878 shares, the days-to-cover ratio is presently 4.0 days. Currently, 3.4% of the shares of the stock are sold short. Currently, 3.4% of the shares of the stock are sold short. Based on an average daily volume of 120,878 shares, the days-to-cover ratio is presently 4.0 days.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HOTH shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Hoth Therapeutics in a research report on Monday, December 22nd. Wall Street Zen cut shares of Hoth Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of Hoth Therapeutics in a report on Thursday, December 4th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $4.50.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of HOTH. Lido Advisors LLC bought a new position in shares of Hoth Therapeutics during the 3rd quarter valued at $32,000. Kestra Private Wealth Services LLC bought a new position in Hoth Therapeutics in the third quarter valued at about $51,000. Geode Capital Management LLC boosted its position in Hoth Therapeutics by 8.0% in the second quarter. Geode Capital Management LLC now owns 122,575 shares of the company’s stock worth $143,000 after purchasing an additional 9,071 shares during the last quarter. Virtu Financial LLC purchased a new position in Hoth Therapeutics in the third quarter worth about $184,000. Finally, Citadel Advisors LLC bought a new stake in shares of Hoth Therapeutics during the 3rd quarter valued at about $232,000. 7.08% of the stock is owned by hedge funds and other institutional investors.

Hoth Therapeutics Price Performance

HOTH traded down $0.01 on Wednesday, hitting $0.99. The company had a trading volume of 196,852 shares, compared to its average volume of 130,648. The stock has a fifty day simple moving average of $1.19 and a 200-day simple moving average of $1.33. The firm has a market capitalization of $15.35 million, a P/E ratio of -0.93 and a beta of 0.64. Hoth Therapeutics has a 52-week low of $0.66 and a 52-week high of $3.80.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.20). Equities research analysts expect that Hoth Therapeutics will post -1.36 earnings per share for the current fiscal year.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.